Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pediatrics Reports
Published in: Current Pediatrics Reports 3/2022

Open Access 01-09-2022 | International Health (EG Lago and N Gupta, Section Editors)

Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances “Take a Village”

Authors: Mariangela Soberón Felín, Kanix Wang, Aliya Moreira, Andrew Grose, Karen Leahy, Ying Zhou, Fatima Alibana Clouser, Maryam Siddiqui, Nicole Leong, Perpetua Goodall, Morgan Michalowski, Mahmoud Ismail, Monica Christmas, Stephen Schrantz, Zuleima Caballero, Ximena Norero, Dora Estripeaut, David Ellis, Catalina Raggi, Catherine Castro, Davina Moossazadeh, Margarita Ramirez, Abhinav Pandey, Kevin Ashi, Samantha Dovgin, Ashtyn Dixon, Xuan Li, Ian Begeman, Sharon Heichman, Joseph Lykins, Delba Villalobos-Cerrud, Lorena Fabrega, José Luis Sanchez Montalvo, Connie Mendivil, Mario R. Quijada, Silvia Fernández-Pirla, Valli de La Guardia, Digna Wong, Mayrene Ladrón de Guevara, Carlos Flores, Jovanna Borace, Anabel García, Natividad Caballero, Claudia Rengifo-Herrera, Maria Theresa Moreno de Saez, Michael Politis, Stephanie Ross, Mimansa Dogra, Vishan Dhamsania, Nicholas Graves, Marci Kirchberg, Kopal Mathur, Ashley Aue, Carlos M. Restrepo, Alejandro Llanes, German Guzman, Arturo Rebellon, Kenneth Boyer, Peter Heydemann, A. Gwendolyn Noble, Charles Swisher, Peter Rabiah, Shawn Withers, Teri Hull, David Frim, David McLone, Chunlei Su, Michael Blair, Paul Latkany, Ernest Mui, Daniel Vitor Vasconcelos-Santos, Alcibiades Villareal, Ambar Perez, Carlos Andrés Naranjo Galvis, Mónica Vargas Montes, Nestor Ivan Cardona Perez, Morgan Ramirez, Cy Chittenden, Edward Wang, Laura Lorena Garcia-López, Guillermo Padrieu, Juliana Muñoz-Ortiz, Nicolás Rivera-Valdivia, María Cristina Bohorquez-Granados, Gabriela Castaño de-la-Torre, Juan David Valencia Hernandez, Daniel Celis-Giraldo, Juan Alejandro Acosta Dávila, Elizabeth Torres, Manuela Mejia Oquendo, José Y. Arteaga-Rivera, Dan L Nicolae, Andrey Rzhetsky, Nancy Roizen, Eileen Stillwaggon, Larry Sawers, Francois Peyron, Martine Wallon, Emanuelle Chapey, Pauline Levigne, Carmen Charter, Migdalia De Frias, Jose Montoya, Cindy Press, Raymund Ramirez, Despina Contopoulos-Ioannidis, Yvonne Maldonado, Oliver Liesenfeld, Carlos Gomez, Kelsey Wheeler, Samantha Zehar, James McAuley, Denis Limonne, Sandrine Houze, Sylvie Abraham, Raphael Piarroux, Vera Tesic, Kathleen Beavis, Ana Abeleda, Mari Sautter, Bouchra El Mansouri, Adlaoui El Bachir, Fatima Amarir, Kamal El Bissati, Ellen Holfels, David Frim, David McLone, Richard Penn, William Cohen, Alejandra de-la-Torre, Gabrielle Britton, Jorge Motta, Eduardo Ortega-Barria, Isabel Luz Romero, Paul Meier, Michael Grigg, Jorge Gómez-Marín, Jagannatha Rao Kosagisharaf, Xavier Sáez Llorens, Osvaldo Reyes, Rima McLeod

Published in: Current Pediatrics Reports | Issue 3/2022

Login to get access

Abstract

Purpose of Review

Review international efforts to build a global public health initiative focused on toxoplasmosis with spillover benefits to save lives, sight, cognition and motor function benefiting maternal and child health.

Recent Findings

Multiple countries’ efforts to eliminate toxoplasmosis demonstrate progress and context for this review and new work.

Summary

Problems with potential solutions proposed include accessibility of accurate, inexpensive diagnostic testing, pre-natal screening and facilitating tools, missed and delayed neonatal diagnosis, restricted access, high costs, delays in obtaining medicines emergently, delayed insurance pre-approvals and high medicare copays taking considerable physician time and effort, harmful shortcuts being taken in methods to prepare medicines in settings where access is restricted, reluctance to perform ventriculoperitoneal shunts promptly when needed without recognition of potential benefit, access to resources for care, especially for marginalized populations, and limited use of recent advances in management of neurologic and retinal disease which can lead to good outcomes.
Appendix
Available only for authorised users
Literature
1.
•• Mcleod R, Mack DG, Boyer K, Mets M, Roizen N, Swisher C, Patel D, Beckmann E, Vitullo D, Johnson D, et al. Phenotypes and functions of lymphocytes in congenital toxoplasmosis. J Lab Clin Med. 1990;116(5):623–35 Parasite specific unresponsiveness in tests of cell mediated immunity in US children with congenital toxoplasmosis.PubMed
2.
McGee T, Wolters C, Stein L, Kraus N, Johnson D, Boyer K, Mets M, Roizen N, Beckman J, Meier P, Swisher C, Holfels E, Withers S, McLeod R. Absence of sensorineural hearing loss in treated infants and children with congenital toxoplasmosis. Otolaryngol Head Neck Surg. 1992;106(1):75–80 Identifies that in the US in treated children sensorineural hearing loss is very rare.PubMedCrossRef
3.
•• Mcleod R, Mack D, Foss R, Boyer K, Withers S, Levin S, Hubbell J. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother. 1992;36(5):1040–8 Presents pyrimethamine pharmacokinetics in infants and children and that treatment can be used safely in the first year as well. Outcomes for some children were markedly better than for comparable children in the literature.PubMedPubMedCentralCrossRef
4.
•• McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N, Wolters C, Stein L, Stein M, Schey W, Remington J, Meier P, Johnson D, Heydemann P, Holfels E, Withers S, Mack D, Brown C, Patton D, McLeod R. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis. 1994;18(1):38–72 Systematic follow up of treated and untreated children and the beginning of a randomized treatment study is described.PubMedCrossRef
5.
•• Swisher CN, Boyer K, McLeod R. Congenital toxoplasmosis. In: Bodensteiner JB (ed). Sem Ped Neurol, 1994;1:4-25. Describes neurologic findings of congenital toxoplasmosis in the United States.
6.
•• Roizen N, Swisher CN, Stein MA, Hopkins J, Boyer KM, Holfels E, Mets MB, Stein L, Patel D, Meier P, Withers S, Remington J, Mack D, Heydemann P, Patton D, McLeod R. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics. 1995;95(1):11–20 Demonstrates better neurologic outcomes and the importance of recognizing that what may be interpreted as developmental delays are really related to visual impairment. This emphasizes the importance of compensatory educational strategies.PubMed
7.
•• Patel DV, Holfels EM, Vogel NP, Boyer KM, Mets MB, Swisher CN, Roizen NJ, Stein LK, Stein MA, Hopkins J, Withers SE, Mack DG, Luciano RA, Meier P, Remington JS, McLeod RL. Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis. Radiology. 1996;199(2):433–40 Identifies that intracranial calcifications in infants with congenital toxoplasmosis resolve or diminish in size with treatment.PubMedCrossRef
8.
•• Vogel N, Kirisits M, Michael E, Bach H, Hostetter M, Boyer K, Simpson R, Holfels E, Hopkins J, Mack D, Mets MB, Swisher CN, Patel D, Roizen N, Stein L, Stein M, Withers S, Mui E, Egwuagu C, et al. Congenital toxoplasmosis transmitted from an immunologically competent mother infected before conception. Clin Infect Dis. 1996;23:1055–60 Identifies that occasionally preconception infection can be transmitted to a fetus even when the pregnant women did not have known immune comprompromise.
9.
•• Mets MB, Holfels E, Boyer KM, Swisher CN, Roizen N, Stein L, Stein M, Hopkins J, Withers S, Mack D, Luciano R, Patel D, Remington JS, Meier P, McLeod R. Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol. 1996;122:309–24 Characterizes ocular toxoplasmosis with congenital infection, that it can be treated effectively without loss of vision in recurrences, and the timing of recurrences especially at school age entry, adolescence, and with significant stress.
10.
•• Roberts F, McLeod R. Pathogenesis of toxoplasmic retinochoroiditis. Parasitol Today. 1999;15:51–7 Identifies pathogenic mechanisms in toxoplasmic retinochoroiditis.PubMedCrossRef
11.
•• Mack DG, Johnson JJ, Roberts F, Roberts CW, Estes RG, David C, Grumet FC, McLeod R. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol. 1999;29:1351–8 Identifies HLA Class II susceptibility alleles.PubMedCrossRef
12.
Lyons RE, Lyons K, McLeod R, Roberts CW. Construction and validation of a polycompetitor construct (SWITCH) for use in competitive RT-PCR to assess tachyzoite-bradyzoite interconversion in Toxoplasma gondii. Parasitology. 2001;123:433–9 Quantitating parasite tachyzoite and bradyzoite burden by pcr.PubMedCrossRef
13.
Brezin AP, Thulliez P, Couvreur J, Nobre R, McLeod R, Mets MB. Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Am J Ophthalmol. 2003;135:779–84 Contrasts retinal disease in French and US children.PubMedCrossRef
14.
•• Boyer KM, Holfels E, Roizen N, Swisher C, Mack D, Remington J, Withers S, Meier P, McLeod R. Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am J Obstet Gynecol. 2005;192:564–71 Identifies risk factors and lack of recognition in congential toxoplasmosis in the US.
15.
•• McLeod R, Khan AR, Noble GA, Latkany P, Jalbrzikowski J, Boyer K. Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. Pediatr Infect Dis J, 2006. 25:270–2 Emphasizes that severe hypersensitivity with sulfonamides can occur with treatment of ocular toxoplasmosis, in this case DRESS syndrome which can be lethal.
16.
•• Roizen N, Kasza K, Karrison T, Mets M, Noble AG, Boyer K, Swisher C, Meier P, Remington J, Jalbrzikowski J, McLeod R, Kipp M, Rabiah P, Chamot D, Estes R, Cezar S, Mack D, Pfiffner L, Stein M, et al. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics. 2006;118:e379–90 Emphasizes effect of visual impairment on measurement of cognition in congenital toxoplasmosis and importance of compensatory strategies.PubMedCrossRef
17.
•• McLeod R, Boyer K, Karrison T, Kasza K, Swisher C, Roizen N, Jalbrzikowski J, Remington J, Heydemann P, Noble AG, Mets M, Holfels E, Withers S, Latkany P, Meier P. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006;42:1383–94 Presents data for the National Collaborative Toxoplasmosis study over 23 years considering pre specified endpoints, comparing the results with two doses of pyrimethamine following randomization, Kaplan Meier analyses of endpoints, documenting substantially better outcomes than in earlier literature.PubMedCrossRef
18.
• Arun V, Noble AG, Latkany P, Troia RN, Jalbrzikowski J, Kasza K, Karrison T, Cezar S, Sautter M, Greenwald MJ, Mieler W, Mets MB, Alam A, Boyer K, Swisher CN, Roizen N, Rabiah P, Del Monte MA, McLeod R. Cataracts in congenital toxoplasmosis. J AAPOS. 2007;11:551–4 Identifies types of cataracts and their treatment in congenital toxoplasmosis.PubMedPubMedCentralCrossRef
19.
• Benevento JD, Jager RD, Noble AG, Latkany P, Mieler WF, Sautter M, Meyers S, Mets M, Grassi MA, Rabiah P, Boyer K, Swisher C, McLeod R. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol. 2008;126:1152–6 Identifies toxoplasmosis as a cause of choroidal neovascular membranes and their successful treatment with ranibizumab and antiparasitic treatment.PubMedPubMedCentralCrossRef
20.
• Phan L, Kasza K, Jalbrzikowski J, Noble AG, Latkany P, Kuo A, Mieler W, Meyers S, Rabiah P, Boyer K, Swisher C, Mets M, Roizen N, Cezar S, Remington J, Meier P, McLeod R. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology. 2008;115:553–59.e8 Follows longitudinal outcomes of ocular disease in congenital toxoplasmosis with less recurrence of retinal disease in treated children.PubMedCrossRef
21.
• Phan L, Kasza K, Jalbrzikowski J, Noble AG, Latkany P, Kuo A, Mieler W, Meyers S, Rabiah P, Boyer K, Swisher C, Mets M, Roizen N, Cezar S, Sautter M, Remington J, Meier P, McLeod R. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol. 2008;146:375–84 Follows longitudinal outcomes of ocular disease in congenital toxoplasmosis with definition of timing of recurrence of retinal disease in children who missed treatment in the first year of life. There were more recurrences in children who missed treatment in the first year of life.PubMedPubMedCentralCrossRef
22.
• Jamieson SE, de Roubaix LA, Cortina-Borja M, Tan HK, Mui EJ, Cordell HJ, Kirisits MJ, Miller EN, Peacock CS, Hargrave AC, Coyne JJ, Boyer K, Bessieres MH, Buffolano W, Ferret N, Franck J, Kieffer F, Meier P, Nowakowska DE, et al. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One. 2008;3:e2285 Discovery of epigenetic influences on the development of congenital toxoplasmosis.
23.
Jamieson SE, Cordell H, Petersen E, McLeod R, Gilbert RE, Blackwell JM. Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo Cruz. 2009;104:162–9 Discusses discovery of susceptibility genes that indicate imprinting and epigenetic influences.
24.
•• Tan T, Mui E, Cong H, Witola W, Montpetit A, Muench S, Sidney J, Alexander J, Sette A, Grigg M, Reed S, Maewal A, Kim S, Boothroyd J, McLeod R. Identification of T. gondii epitopes, adjuvants, & host genetic factors that influence protection of mice & humans. Vaccine. 2010;28:3977–89 Identification of susceptibility gene in NCCCTS cohort, establishing MHC Class I pathway processing by ERAAP. Parts of initial steps in development of a vaccine to prevent toxoplasmosis in humans which is ongoing with expanding approaches. Demonstration of powerful adjuvant effect of GLA-SE in HLA transgenic mice.
25.
Lees MP, Fuller SJ, McLeod R, Boulter NR, Miller CM, Zakrzewski AM, Mui EJ, Witola WH, Coyne JJ, Hargrave AC, Jamieson SE, Blackwell JM, Wiley JS, Smith NC. P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. J Immunol. 2010;184:7040–6 Susceptibility gene for congenital toxoplasmosis which influences outcomes, affecting cytokines and cell death.PubMedCrossRef
26.
Jamieson SE, Peixoto-Rangel AL, Hargrave AC, Roubaix LA, Mui EJ, Boulter NR, Miller EN, Fuller SJ, Wiley JS, Castellucci L, Boyer K, Peixe RG, Kirisits MJ, Elias Lde S, Coyne JJ, Correa-Oliveira R, Sautter M, Smith NC, Lees MP, et al. Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosis. Genes Immun. 2010;11:374–83 Susceptibility gene for congenital toxoplasmosis which influences outcomes, affecting cytokines and cell death.PubMedPubMedCentralCrossRef
27.
• Noble G, Latkany P, Kusmierczyk J, Mets M, Rabiah P, Boyer K, Jalbrzikowski J, Wroblewski K, Karrison T, Swisher C, Mieler W, Meier P, McLeod R. Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Sci Med. 2010;20:20–6 Finds 10 percent of mothers of infants in the US who have congenital toxoplasmosis have retinal lesions, emphasizing importance of performing eye examinations of mothers of children with congenital toxoplasmsosis.
28.
• Witola WH, Mui E, Hargrave A, Liu S, Hypolite M, Montpetit A, Cavailles P, Bisanz C, Cesbron-Delauw MF, Fournié GJ, McLeod R. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun. 2011;79:756–66 Identifies susceptibility gene to congenital toxoplasmosis determining functioning of the inflammasome.PubMedCrossRef
29.
Delair E, Latkany P, Noble AG, Rabiah R, McLeod R, Brezin A. Clinical Manifestations of Ocular Toxoplasmosis. Ocul Immunol Inflamm. 2011;2:91–102 Collates and presents clinical manifestations of ocular toxoplasmosis in a pictoral collection.
30.
Hill D, Coss C, Dubey JP, Wroblewski K, Sautter M, Hosten T, Munoz-Zanzi C, Mui E, Withers S, Boyer K, Hermes G, Coyne J, Jagdis F, Burnett A, McLeod P, Morton H, Robinson D, McLeod R. Toxoplasmosis Study Group. Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol. 2011;97:328–37 Identifies antigen in sporozoites oocysts that elicits an antibody response present for the half life of that antibody, about 8 months in human serum following exposure. Also identifies high prevalence of infection in Lancaster Pennsylvania Amish family/persons. 
31.
• Stillwaggon E, Carrier CS, Sautter M, McLeod R. Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis. 2011;5:e1333 Demonstrates parameters that lead to cost effective screening for Toxoplasma infection acquired in gestation. This suggests strategies important in this model for lowering costs for diagnosis and treatment to facilitate programs for screening.
32.
• Boyer K, Hill D, Mui E, Wroblewski K, Karrison T, Dubey JP, Sautter M, Noble AG, Withers S, Swisher C, Heydemann P, Hosten T, Babiarz J, Lee D, Meier P, McLeod R. Toxoplasmosis Study Group. Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis. 2011;53:1081–9 Identifies epidemics of acute acquired Toxoplasma infection in NorthAmerica and that ingestion of oocysts may go unrecognized.
33.
•• McLeod R, Boyer K, Lee D, Mui E, Wroblewski K, Karrison T, Noble AG, Withers S, Swisher CN, Heydemann PT, Sautter M, Babiarz J, Rabiah P, Meier P, Grigg M. Prematurity & Severity Associate with T. gondii Alleles (NCCCTS, 1981-2009). Clin Infect Dis. 2012;54:1595–605 Defines serotypes of T. gondii and their distribution in the United States, and associations of Toxoplasma genotypes with phenotypes of illness including prematurity and severity of illness.
34.
• Lai BS, Witola WH, El Bissati K, Zhou Y, Mui E, Fomovska A, McLeod R. Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci U S A. 2012;109:14182–7 Identification or validation of molecular targets in Toxoplasma and that they can be targeted with antisense as potential for medicines.
35.
• Burrowes D, Boyer K, Swisher CN, Noble AG, Sautter M, Heydemann P, Rabiah P, Lee D, McLeod R. Toxoplasmosis Study Group. Spinal Cord Lesions in Congenital Toxoplasmosis Demonstrated with Neuroimaging, Including Their Successful Treatment in an Adult. J Neuroparasitology. 2012;3:1–8 Chronic active toxoplasmosis in an adult and its effective treatment proves that this can occur in the brain and spinal cord, not only the eye, and that it can resolve with treatment.CrossRef
36.
Béla SR, Dutra MS, Mui E, Montpetit A, Oliveira FS, Oliveira SC, Arantes RM, Antonelli LR, McLeod R, Gazzinelli RT. Impaired Innate Immunity in Mice Deficient in Interleukin-1 Receptor-Associated Kinase 4 Leads to Defective Type 1 T Cell Responses, B Cell Expansion, and Enhanced Susceptibility to Infection with Toxoplasma gondii. Infect Immun. 2012;80:4298–308 Susceptibility gene and its mechanism in congenital toxoplasmosis.PubMedPubMedCentralCrossRef
37.
• Witola W, Liu S, Montpetit A, Hypolite M, Zhou Y, Mui E, Cesbron-Delauw MF, Fournie G, Cavailles P, Bisanz C, Boyer K, Withers S, Noble AG, Swisher C, Heydemann P, Rabiah P, McLeod R. ALOX12 In Human Toxoplasmosis. Infect Immun. 2014;82(7):2670–9 Susceptibility genes and their mechanisms in congenital toxoplasmosis.PubMedPubMedCentralCrossRef
38.
• McLeod R. Editorial on Lago EG Utility and limitations of T. gondii-specific IgM serum antibodies in the diagnosis of congenital toxoplasmosis in Porto Alegre. J Pediatr (Rio J). 2014;90(4):329–31 Emphasizes that many infants with congenital toxoplasmosis have negative anti-Toxoplasma IgM at birth. When present in the neonate, IgM usually becomes negative very early.
39.
•• McLeod R, Lykins J, Noble AG, Rabiah P, Swisher C, Heydemann P, McLone D, Frim D, Withers S, Clouser F, Boyer K. Management of Congenital Toxoplasmosis. Curr Pediatr Rep. 2014;2(3):166–94 Provides Guidelines and overview of supporting evidence for management of congenital toxoplasmosis based in the US experience.CrossRef
40.
• Hutson SL, Wheeler KM, McLone D, Frim D, Penn R, Swisher CN, Heydemann PT, Boyer KM, Noble AG, Rabiah P, Withers S, Montoya JG, Wroblewski K, Karrison T, Grigg ME, McLeod R. Patterns of Hydrocephalus Caused by Congenital Toxoplasma gondii Infection and Association with Parasite Strain. Clin Infect Dis. 2015;48:58 Pattern of hydrocephalus associates with parasite serotype although not completely suggesting different epitopes may be critical or that there may be multifactorial influences.
41.
• Contopoulos-Ioannidis D, Wheeler KM, Ramirez R, Press C, Mui E, Zhou Y, Van Tubbergen C, Prasad S, Maldonado Y, Withers S, Boyer KM, Noble AG, Rabiah P, Swisher CN, Heydemann P, Wroblewski K, Karrison T, Grigg ME, Montoya JG, McLeod R. Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis. 2015;61(12):1815–24 Emphasizes that toxoplasmosis occurs in families, living groups likely exposed to the same risk factors.PubMedPubMedCentralCrossRef
42.
•• McLeod R, Wheeler KM, Boyer K. Reply to Wallon and Peyron. Clin Infect Dis. 2016;62(6):812–4 Emphasizes that favorable outcomes in treated toxoplasmosis are due to treatment.PubMedCrossRef
43.
•• Begeman IJ, Lykins J, Zhou Y, Lai BS, Levigne P, El Bissati K, Boyer K, Withers S, Clouser F, Noble AG, Rabiah P, Swisher CN, Heydemann PT, Contopoulos-Ioannidis DG, Montoya JG, Maldonado Y, Ramirez R, Press C, Stillwaggon E, et al. Point-of-care testing for Toxoplasma gondii IgG/IgM using Toxoplasma ICT IgG-IgM test with sera from the United States and implications for developing countries. PLoS Negl Trop Dis. 2017;11:e0005670 All sera from persons NCCCTS including all serotypes and acute, subacute and chronic, detected with 100% sensitivity and specificity. Considers spillover benefit and clinical implications.
44.
•• Lykins J, Li X, Levigne P, Zhou Y, El Bissati K, Clouser F, Wallon M, Morel F, Leahy K, El Mansouri B, Siddiqui M, Leong N, Michalowski M, Irwin E, Goodall P, Ismail M, Christmas M, Adlaoui EB, Rhajaoui M, et al. Rapid, inexpensive, fingerstick, whole-blood, sensitive, specific, point-of-care test for antiToxoplasma antibodies. PLOS Negl Trop Dis. 2018;12(8):e0006536 Whole blood obtained by fingerstick is an efficient and accurate way to screen for Toxoplasma seropositiity with 100%sensitiity and specificity.PubMedPubMedCentralCrossRef
45.
Lykins J, Wang K, Wheeler K, Clouser F, Dixon A, El Bissati K, Zhou Y, Lyttle C, Rzhetsky A, McLeod R. Understanding Toxoplasmosis in the United States through “Large Data” Analyses. Clin Infect Dis. 2016;63(4):468–75 Initial effort to understand the magnitude and implications of Toxoplasma infection of humans in the U.S. Editorial by E.Wing. Editors choice.
46.
• Peyron F, McLeod R, Ajzenberg D, Contopoulos-Ioannidis D, Kieffer F, Mandelbrot L, Sibley D, Pelloux H, Villena I, Wallon M, Montoya J. Congenital Toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches. PLoS Neglected Tropical Diseases. 2017;1(2):e0005222 Contrasts gestational screening in France facilitating early treatment with delays that are the norm in the United States.
47.
Ngô HM, Zhou Y, Lorenzi H, Wang K, Kim TK, Zhou Y, El Bissati K, Mui E, Fraczek L, Rajagopala SV, Roberts CW, Henriquez FL, Montpetit A, Blackwell JM, Jamieson SE, Wheeler K, Begeman IJ, Naranjo-Galvis C, Alliley-Rodriguez N, Davis RG, Soroceanu L, Cobbs C, Steindler DA, Boyer K, Noble AG, Swisher CN, Heydemann PT, Rabiah P, Withers S, Soteropoulos P, Hood L, McLeod R. Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Sci Rep (Nature). 2017;7(1):11496. https://​doi.​org/​10.​1038/​s41598-017-10675-6Using a systems biology analysis of genetics, transcriptomics, proteomics, serum and miR biomarkers, upstream regulators, protein association string, immunohistochemistry, and human MM6 (myeloid) and primary human brain neuronal stem cells, disease association analyses,it was found thatmodulates signature pathways of human epilepsy, neurodegeneration and cancer. This has important implications for the 2 billion people who have this parasite in their brains across lifetimes, including in Panama, Colombia and the United States, making the seroprevalence of 85% in Panama adults over the age of 65 years potentially of considerable significance for those later in life.
48.
•• El Bissati K, Levigne P, Lykins J, Adlaoui EB, Barkat A, Berraho A, Laboudi M, El Mansouri B, Ibrahimi A, Rhajaoui M, Quinn F, Murugesan M, Seghrouchni F, Gómez Marín JE, Peyron F, McLeod R. Global initiative for congenital toxoplasmosis: an observational and international comparative clinical analysis. Emerging Microbes & Infections. 2018;7:165. https://​doi.​org/​10.​1038/​s41426-018-0164-4Introduces the concept of the ongoing global initiative to eliminate toxoplasmosis.CrossRef
49.
Aguirre AA, Longcore T, Barbieri M, Dabritz H, Hill D, Klein PN, Lepczyk C, Lilly EL, McLeod R, Milcarsky J, Murphy CE, Su C, VanWormer E, Yolken R, Sizemore GC. The One Health Approach to Toxoplasmosis: Epidemiology, Control, and Prevention Strategies. Ecohealth. 2019. https://​doi.​org/​10.​1007/​s10393-019-01405-7. Considers Toxoplasma as part of a “one health” initiative including cat excrement exposure and what could be done to improve water systems and eliminate contamination due to oocysts.
50.
• McLone D, Frim D, Penn R, Swisher CN, Heydemann P, Boyer K, Noble AG, Rabiah P, Withers S, Wroblewski K, Karrison T, Hutson S, Wheeler K, Cohen W, Lykins J, McLeod R. Outcomes of hydrocephalus secondary to congenital toxoplasmosis. J Pediatric Neurosurg. https://​doi.​org/​10.​3171/​2019.​6.​PEDS186842019Documents that prompt treatment including needed neurosurgery placement of ventriculoperitoneal shunts can result in favorable, and best of the outcomes.
51.
• Wallon M, Stillwaggon E, Sawyer L et al. Prevention of congenital toxoplasmosis in France using prenatal screening: A decision-analytic economic model PLOS ONE In Press 2022. Improved outcome with screening and treatment in utero.
52.
Mandelbrot L, Kieffer F, Wallon M, Winer N, Massardier J, Picone O, Fuchs F, Benoist G, Garcia-Meric P, L'Ollivier C, Paris L, Piarroux R, Villena I, Peyron F. Toxoplasmosis in pregnancy: Practical Management. Gynecol Obstet Fertil Senol. 2021;49(10):782-91. https://​doi.​org/​10.​1016/​j.​gofs.​2021.​03.​003Presents a contrast of France with strong screening program and treatment. US clinicians and Scientists trying to build a comparable program.
53.
•• Prusa AR, Kasper DC, Sawers L, Walter E, Hayde M, Stillwaggon E. Congenital toxoplasmosis in Austria: prenatal screening for prevention is cost-saving. PLoS Negl Trop Dis. 2017;11(7):e0005648 Fourteen-fold cost savings, with efficacy that has transformed outcomes of congenital infection in Austria with use of pre-natal screening. Goal herein is to scale up such programs worldwide to benefit individual patients and societies with spill over benefit for maternal and child health.
54.
Kosack CS, Pasge AL, Klatser PR. A guide to aid the selection of diagnostic tests. Bull World Health Organ. 2017;95(9):639–45 Guide to diagnostic tests prepared by WHO.PubMedPubMedCentralCrossRef
55.
•• Gomez CA, Budvytyte LN, Press C, Zhou L, McLeod R, Maldonado Y, Montoya JG, Contopoulos-Ioannidis DG. Evaluation of three point-of-care (POC) tests for detection of Toxoplasma immunoglobulin IgG and IgM in the United States: proof of concept and challenges. Open For Inf Dis. 2018. https://​doi.​org/​10.​1093/​ofid/​ofy215High sensitivity and specificity of LDBio used with sera.
56.
•• Stillwaggon E, Carrier CS, Sautter M, McLeod R. Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis. 201;5(9):e1333. Dec 10(1):1675-1682. https://​doi.​org/​10.​1080/​22221751.​2021.​1948359. Supplement. Equations for determining cost efficacy of gestational screening for acquisition of Toxoplasma during gestation. This is to facilitate prompt treatment to prevent congenital infection and/or its sequelae.
57.
• El Mansouri B, Amarir F, Peyron F, Adlaoui EB, Piarroux R, El Abassi M, Lykins J, Nekkal N, Bouhlal N, Makkaoui M, Barkat A, Lyaghfouri A, Zhou Y, Rais S, Daoudi F, Ismail Elkoraichi I, Zekri M, Nezha B, Hajar M, et al. Performance of a novel point-of-care blood test for Toxoplasma infection in women from diverse regions of Morocco. Microbes Infect. 2021;10(1):1675–82. https://​doi.​org/​10.​1080/​22221751.​2021.​1948359 High prevalence of Toxoplasma infection in Morocco, LDBio can be used for diagnosis with high sensitivity and specificity, infection was associated with poverty, well water, not washing fruits and vegetables.
58.
•• Grose A, Wallon M, Chapey E, Leahy K, Zhou Y, Siddiqui M, Leong N, Goodall P, Tesic V, Beavis K, Houze S, Abraham S, Limonne D, Piarroux R, McLeod R, Eliminating Confounding False Positive IGMtests by Using a Lateral Immunochromatography Test that meets WHO ASSURED Criteria In submission, 2022. Demonstrates that LDBio can eliminate problems from false positive IgMs in serologic screening programs for congenital toxoplasmosis for those without anti T.gondii IgG antibody.
59.
• Flores C, Villalobos-Cerrud D, Borace J, Mcleod R, Fábrega L, Norero X, Sáez-Llorens X, Moreno MT, Restrepo CM, Llanes A, Mario Quijada RM, Ladrón De Guevara M, Guzmán G, de la Guardia V, García A, Wong D, Reyes O, Soberon M, Caballero EZ. Prevalence and risk factors associated with T. gondii infection in pregnant women and newborns from Panama. Pathogens. 2021;10(6):764. https://​doi.​org/​10.​3390/​pathogens1006076​4Identifies areas of high risk in Panama, high frequency of infections, and role of exposure to pet animals.PubMedPubMedCentralCrossRef
60.
•• Mandelbrot L, Kieffer F, Sitta R, Laurichesse-Delmas H, Winer N, Mesnard L, Berrebi A, Le Bouar G, Bory J-P, Cordier A-G, Ville Y, Perrotin F, Jouannic J-M, Biquard F, d’Ercole C, Houfflin-Debarge V, Villena I, Thiébaut R Toxoges. Prenatal therapy with pyrimethamine + sulfadiazine versus spiramycin to reduce placental transmission of toxoplasmosis: A multicenter, randomized trial. Am J Obstetr Gynecol. 2018. https://​doi.​org/​10.​1016/​j.​ajog.​2018.​05.​031Demonstrates that outcomes can be highly favorable with serologic screening in gestation and prompt treatment, with slight improvement in outcomes with pyrimethamine and sulfadiazine compared to spiramycin treatment after 16 weeks gestation defined as 16 weeks of amennhorea.
61.
McLeod R., Sautter M,, Rooney T, Morel J, Taub L, Taub D, Taub V, Taub JW, Tirado S, Latkany P, Boyer K, Hotez P, Lin E, McLone D, et al. Submission to the Committee on Public Health Illinois State Senate. Regarding: Prenatal and Neonatal Congenital Toxoplasmosis Prevention and Treatment Act, SB3667 in the context of the National Collaborative Chicago Based Congenital Toxoplasmosis Study. 2010. Introduction of a bill to have a law that obstetricians in Illinois offer their patients the opportunity to have serologic testing in gestation, in Illinois. This provided information from patients, families, physicians, scientists. Committee favored law.
62.
63.
Gomez-Marín JE, Munoz-Ortiz J, Mejía-Oquendo M, Arteaga-Rivera JY, Rivera-Valdivia N, Bohorquez-Granados MC, Velasco-Velasquez S, Castano-de-la-Torre G, Acosta-Davila JA, García-Lopez LL, Torres-Morales E, Vargas M, Valencia JD, Celis-Giraldo D, de-la-Torre A. High frequency of ocular toxoplasmosis in Quindío, Colombia and risk factors related to the infection. Heliyon. 2021;7:e06659 Identifies high prevalence of ocular toxoplasmosis in Quindio, Colombia and associated risk factors. Importance of drinking bottled water associated with prevention was identified.
64.••
McLeod R, Cohen W, Dovgin S, Finkelstein L, Boyer K. Human Toxoplasmosis. In: Weiss LM, Kim K, editors. The Model apicomplexan: Perspectives and Methods Third Edition. Chapter 4: Elsevier; 2020. p. 117–228. Comprehensive up to date consideration of human toxoplasmosis, including clinical aspects, treatment, prevention, other considerations of pathogenesis, unifying concepts and toward the future.
65.
Mejia-Oquendo M, Marulanda-Ibarra E, Gomez-Marin JE. Evaluation of the impact of the first evidence-based guidelines for congenital toxoplasmosis in Armenia (Quindío) Colombia: An observational retrospective analysis. The Lancet Regional Health - Americas (In Press, 2021). Between 2001 and 2019, the national guideline has had a positive impact by improving early diagnosis and treatment of prenatal toxoplasmosis and reducing severe forms, as observed at the referral center.
66.
•• Kieffer F, Wallon M, Garcia P, Thulliez P, Peyron F. Franck ?Risk factors for retinochoroiditis During the firat 2 years of life in infants with treated Congenital toxoplasmosis. J. Pediatr Infect Dis J. 2008;27(1):27–32. https://​doi.​org/​10.​1097/​INF.​0b013e318134286d​Defines risk factors for active disease in the first two years of life in children with treated congenital disease. “3 factors were significantly associated with first retinochoroiditis before the age of 2 years: a delay of >8 weeks between maternal seroconversion and first treatment [hazard ratio, 2.54; 95% confidence interval (CI), 1.14-5.65], female gender (hazard ratio, 2.02; 95% CI, 1.01-4.1), and cerebral calcifications at birth (hazard ratio, 4.3; 95% CI, 1.9-10). There was no correlation between gestational age at the time of maternal infection and risk for retinochoroiditis.”.PubMedCrossRef
67.
•• Wallon M, et al. Congenital Toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin. Infect. Dis. 2013;56:1223–31 Demonstrates prenatal screening and treatment decreases transmission rate and improves clinical outcome at age 3 years.PubMedCrossRef
68.
•• Montoya JG, Laessig K, Sohail Fazeli M, Siliman G, Yoon SS, Drake-Shanahan E, Zhu C, Akbary A, McLeod R. A Fresh Look at the Role of Spiramycin in Preventing a Neglected Disease: Meta-analyses of Observational Studies. Eur J Med Res. 2021;I26(1):143. https://​doi.​org/​10.​1186/​s40001-021-00606-7Meta-analysis shows contribution of spiramycin to prevention and improved outcomes of congenital toxoplasmosis. Recent work by Mandelbrot et al suggests its most important role is in the first 14 weeks of gestation trimester when pyrimethamine may be teratogenic.CrossRef
69.
McLeod R, Lee D, Clouser F, Boyer K (2015). Toxoplasmosis in the Fetus and Newborn Infant. In: Stevenson D, Sunshine P (eds) Neonatology: Clinical Practice and Procedures. 1st ed. New York: McGraw Hill, pp 821-76. Comprehensive review of data concerning toxoplasmosis in the fetus and newborn infant with images.
70.
McLeod R, Lee D, Clouser F, Boyer K. Diagnosis of Congenital Toxoplasmosis. In: Stevenson D, Sunshine P, editors. Neonatology: Clinical Practice and Procedures. 1st ed. New York: McGraw Hill; 2015. p. 1297–310. Atlas of images of congenital toxoplasmosis and its diagnosis and treatment.
71.••
McLeod R, Boyer K. Toxoplasmosis. In: Behrman RL, Kliegman R, Arvin AM, editors. In Nelson’s Textbook of Pediatrics, 2 2ndt Ed. Philadelphia: WB Saunders; 2021. In Press. Most current chapter summarizing newer aspects of Toxoplasmosis in 2022.
72.
•• Remington JS, McLeod R, Thulliez P, Desmonts G, Toxoplasmosis. Infectious Diseases of the Fetus and Newborn Infant. Ch 31. Elsevier. 6th edition pp. 947-1091.2006. Detailed, thorough chapter that presents data and images of toxoplasmosis in the fetus and newborn infant.
73.
•• Hotez PJ. Neglected Infections of Poverty in the United States of America P 2008;2(6):e2. PLoS Neglect Trop Dis. Demonstrates and emphasizes that the diseases noted to occur in developing countries also occur in the United States , especially in areas of poverty. These include toxoplasmosis, which affects persons of all demographics.
74.
•• Lago EG, Endres MM, Scheeren MFDC, Fiori. Ocular Ourcome of Brazilian Patients with. Congenital toxoplasmosis. Pediatr Infect Dis J. 2021 Jan;40(1):e21–7. https://​doi.​org/​10.​1097/​INF.​0000000000002931​Part of a series of papers by Lago et al, demonstrating severity of congenital toxoplasmosis in Brazil, manifestations, efficacy of treatment, and the associated high incidence of new retinochoroidal lesions during the follow-up period . The latter indicates the importance of long-term follow-up of patients with congenital toxoplasmosis. Initiating treatment within the first 4 months of life, especially within the first 2 months, was a protective factor against the later development of retinochoroiditis.PubMedCrossRef
75.
•• Silva Machado A, et al. Biomarker Analysis Revealed Distinct Profiles of Innate and Adaptive immunity in Infants with ocular lesions of Congenital toxoplasmosis. Sci Rep. 2014:2020. Active retinal lesions associated with leukocytosis with monocytes and NK cells CD8+ T cells, possibly predicting morbidity.
76.
Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med. 1994;330:1858 Newborn screening program in Massachusetts, New Hampshire and ermont detects congenital toxoplasmosis not otherwise recognized at birth with approximately half with retinal or central nervous system signs with careful evaluation.
77.
Dubey JP, Lago EG. Gennari SM. Su C, Jones JL. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology. 10 July 2012 Comprehensive review of toxoplasmosis in Brazil.
78.
79.
•• Pomares C, Zhang B, Arulkumar S, Gonfrier G, Marty P, Zhao S, Cheng S, Tang M, Dai H, Montoya JG. Validation of IgG, IgM multiplex plasmonic gold platform in French clinical cohorts for the serodiagnosis and follow-up of Toxoplasma gondii infection. Diagn Microbiol Infect Dis. 2017;87(3):213–8. https://​doi.​org/​10.​1016/​j.​diagmicrobio.​2016.​09.​001Inexpensive serum and saliva nanotest diagnoses Toxoplasma infection.
80.
•• Li X, Pomares C, Peyron F, Press CJ, Ramirez R, Gonfrier G, Cannavo I, Chapey E, Levigne P, Wallon M, Montoya JG, Hongjie DH. Plasmonic gold chips for the diagnosis of Toxoplasma gondii, CMV, and rubella infections using saliva with serum detection precision. Eur J Clin Microbiol Infect Disj. 2019;38(5):883–90. https://​doi.​org/​10.​1007/​s10096-019-03487-1Nanogold test can be multiplexed for perinatal infections with high sensitivity and specificity.CrossRef
81.
•• Abraham S, McLeod R, Houhou-Fidouh, Nicaise-Rolland P, Landraud L, Houze S. Performances of Toxoplasma ICT IgG-IgM in comparison with Vidas Toxo Competition and Toxoscreen, Lyon France European meeting. Lateral Chromatography test highly sensitive and specific when testing sera from persons in France and the USA. Also In submission 2022.
82.
Ben-Abdallah R et al. Contribution of the Toxoplasma ICT IgG IGM test in determining the immune status of pregnant women against toxoplasmosis. 2021. https://​doi.​org/​10.​1002/​jcla23749. Lyon France European meeting. ICTLateral immunochromatography test sensitive and specific with sera in Algeria.
83.
Cardosa L, Piarroux R. Lopes APInterest du test Toxoplasma ICT IgG-IgM dans le diagnostic serologique de l’infection a Toxoplasma gondi chez le chat. Lyon Parasitology Meeting. In Press 2022. POC test also of use for detection of infection in cats but not as sensitive and specific as humans.
84.
•• McPhillie M, Zhou Y, El Bissati K, Dubey J, Lorenzi H, Capper M, Lukens AK, Hickman M, Muench S, Verma SK, Weber CR, Wheeler K, Gordon J, Sanders J, Moulton H, Wang K, Kim TK, He Y, Santos T, et al. New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections. Sci Rep. 2016;6:29179. https://​doi.​org/​10.​1038/​srep29179Brazilian strain of Toxoplasma, EGS, grows as a slowly replicating encysted organism in tisuue culture identifying cytochrome b qi domain as critical for this lifecycle stage. This is used to develop an inhibitor of this molecular target in Toxoplasma amd Plasmodia.PubMedPubMedCentralCrossRef
85.
•• McPhillie M, Zhou Y, Hickman M, Gordon J, Weber C, Li Q, Lee P, Amporndanai K, Johnson RH, Darby H, Woods S, Li ZH, Priestley R, Ristroph K, Biering GC, El Bissati K, Hwang S, Hakim FE, Dovgin S, et al. Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites. Front Cell Infect Microbiol. 2020;10:203. https://​doi.​org/​10.​3389/​fcimb.​2020.​00203JAG21 is potent against tachyzoites, bradyzoites of toxoplasma, completely curative with prompt treatment. If begun in vivo after 15 days in vivo a small proportion of cysts (<50%) remain. Effective at low nM amounts in single oral dose also against P berghei three life cycle stages. “Persister” of a model parasite rps 13 delta that has exited the cell cycle shows overlapping molecular targets with P. cynomogoli hypnozoites single cell RNA seq providing insight into and model system to test which genes are transcribed in the small numbers of persisters.PubMedPubMedCentralCrossRef
86.
•• McPhillie M, ZhouY HM, Gordon J, Weber C, Li Q, Lee P, Amporndanai K, Johnson RH, Darby H, Woods S, Li ZH, Priestley R, Ristroph K, Biering GC, El Bissati K, Hwang S, Hakim FE, Dovgin S, Lykins J, et al. Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites. Front Cell Infect Microbiol. 2020; Microbiol Ebook with editorial by de-la-Torre A and Gomez-Marin JE that states:” “Finally, one major finding reported in this Research Topic is the development of a powerful tetrahydroquinolone, JAG21, which can eliminate apicomplexan parasites in tissues (McPhillie et al.). This is an extraordinary achievement in in vivo models because, until now, there are no drugs that can eliminate tissue cysts of the parasite responsible for reactivations during the host’s period of life. The authors created a next generation lead compound with high in vitro and in vivo efficacy against T.gondii tachyzoites, bradyzoites, and established encysted organisms (McPhillie et al). This compound is promising and deserves further development through preparation of advanced formulations and testing in further studies of pharmacokinetics, efficacy, and safety. In summary, this Research Topic shows significant advances made in the study of T. gondii using in-vitro, in-vivo and animal models. The results presented here will illuminate the pathway to create an effective clinical response to this public health key issue.”.
87.
••Lykins JD, Filippova EV, Halavaty AS, Minasov G, Zhou Y, Dubrovska I, Flores KJ, Shuvalova LA, Ruan J, El Bissati K, Dovgin S, Roberts CW, Woods S, Moulton JD, Moulton H, McPhillie MJ, Muench SP, Fishwick CWG, Sabini E, Shanmugam D, Roos DS, McLeod R, Anderson WF, Ngô HM. CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in Toxoplasma gondii. Front Cell Infect Microbiol. 2018;8:352. https://​doi.​org/​10.​3389/​fcimb.​2018.​00352. eCollection 2018. Crystalography pipeline identifies potential molecular targets (enzymes) in Toxoplasma gondii;Vivo morpholinos and crispr cas 9 screen together demonstrate which is essential in tachyzoites.
88.
••Eichenwald HF. A study of congenital toxoplasmosis with particular emphasis on clinical manifestations, sequelae and therapy. In: Human Toxoplasmosis, Siim JC (Ed), Munksgaard, Copenhagen 1959. Congenital toxoplasmosis with generalized or neurologic presentation in the US if untreated or treated only one month causes substantial neurologic and eye disease by the age of 4 years with significant morbidity.
89.
••Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986;1:254 Apparently asymptomatic infants develop adverse visual sequellae of congenital toxoplasmosis by teensge years.PubMedCrossRef
90.
Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics. 1980;66:767 Apparently asymptomatic infants develop adverse retinal and central nervous system sequellae of congenital toxoplasmosis.PubMedCrossRef
91.
92.
93.
94.
Ryning FW, Mcleod R, Maddox JC, Hunt S, Remington JS. Probable transmission of Toxoplasma gondii by organ transplantation. Ann Intern Med. 1979;90(1):47–9. Patient who received a cardiac transplant donated from a person who died in a motorcycle accident who had acute toxoplasmosis. The recipient of this infected donor organ developed brain abscesses and encephalitis due to Toxoplasma gondii. His toxoplasmic brain disease responded to many months of treatment with pyrimethamine, sulfadiazine and leucovorin demonstrating this infection could be treated in such immune compromised persons when treatment was continued throughout the immune compromise until resolution of brain involvement.
95.
Levin M, Mcleod R, Young Q, Abrahams C, Chambliss M, Walzer P, Kabins SA. Pneumocystis pneumonia: importance of gallium scan for early diagnosis and description of a new immunoperoxidase technique to demonstrate Pneumocystis carinii. Am Rev Respir Dis. 1983;128(1):182–5 Initial patient with toxoplasmic encephalitis in the Midwest and eleventh in the United States with multiple opportunistic infections at the outset of the AIDS epidemic. His toxoplasmic encephalitis responded to treatment with pyrimethamine sulfadizune given with leucovorin.
96.
Dubey JP Schizogony and gametogony of oocyst-deficient T-263 strain of Toxoplasma gondi. Vet Parasitol. 2017;245:160-162. doi: https://​doi.​org/​10.​1016/​j.​vetpar.​2017.​05.​024. T-263 cannot make life cycle stages beyond schizonts, male and female gametes. This chemically mutagenized parasite clone is an effective accine when administered orally in separate study eliminating endemic toxoplasmic infections on a pig farm in southern Illinois when administered to cats on this farm. Subsequent analysis of this clone provides a rosetta stone to merozoite development and capacitation preparing for Conception of Toxoplasma gondii (McLeod et al in submission, 2022).
97.
Ramakrishnan C, Maier S, Walker R, et al. An experimental genetically attenuated live vaccine to prevent transmission of Toxoplasma gondii by cats. Scientific Reports. 2019;9:1474 “RNA-Seq analysis of cat enteric stages of T. gondii uncovered genes expressed uniquely in microgametes and macrogametes. A CRISPR/Cas9 strategy was used to create a T. gondii strain that exhibits defective fertilization, decreased fecundity and generates oocysts that fail to produce sporozoites. Inoculation of cats with this engineered parasite strain totally prevented oocyst excretion following infection with wild-type T. gondii, demonstrating that this mutant is an attenuated, live, transmission-blocking vaccine.” Description from reference 97.
98.
••Alvarez C, de-la-Torre A, Vargas M, Herrera C, Uribe-Huertas LD, Lora F, Gómez-Marín JE. Striking Divergence in Toxoplasma ROP16 Nucleotide Sequences From Human and Meat Samples. JID. 2015;211(15 June):2006 Association of Rop 16 type 1/3 variant with ocular toxoplasmosis in Colombia demonstrated by sequence and peptide elisa testing of sera is not the predominant organism found in meat samples. Variation in storage processes and hygenic factors differed in stores selling meat in Quindio, Armenia Colombia.PubMedCrossRef
99.
••Hutson SL, Mui E, Kinsley K, Witola WH, Behnke MS, El Bissati K, Muench SP, Rohrman B, Liu SR, Wollmann R, Ogata Y, Sarkeshik A, Yates JR 3rd, McLeod R T. gondii RP promoters & knockdown reveal molecular pathways associated with proliferation and cell-cycle arrest. PLoS One. 2010;5:e14057 Gi arrested tetracycline regulated mutant RH strain parasite is a dormant persisting parasite when tetracycline regulating and leading to transcription of the the small ribosomal protein 13 (RPS13) gene is absent. This organism can recrudesce after very long times in tissue culture exceeding 6 months demonstrating effect of ribosomal stress secondary to protein starvation. This mutated parasite is a highly effective vaccine for mice.
100.
101.
••de Mourn L, Bahia-Oliveira G, Maria L, Wada MY, Jones JL, Tuboi SH, Carmo EH, Ramalho WM, Camargo NJ, Trevisan R, Graça RMT, da Silva AJ, Moura I, Dubey JP, Garrett DO. Waterborne Toxoplasmosis, Brazil, from Field to Gene. Emerg Infect Dis. 2006;12(2):326–9. https://​doi.​org/​10.​3201/​eid1202.​041115Waterborn epidemics of toxoplasmosis in Brazil.CrossRef
102.
••Tan TG, Mui E, Cong H, Witola W, Montpetit A, Muench S, Sidney J, Alexander J, Sette A, Grigg M, Reed S, Maewal A, Kim S, Boothroyd J, McLeod R. Identification of T. gondii epitopes, adjuvants, & host genetic factors that influence protection of mice & humans. Vaccine. 2010;28:3977–89 Creation and understanding of vaccines foundational for creation of immunosense vaccines to prevent Toxoplasma infection in humans.
103.
••El Bissati K, Zhou Y, Paulillo S, Raman SK, Karch C, Roberts CW, Burkhard P, McLeod R. Novel protein nanovaccine confers robust immunity against Toxoplasma. Nature (NPJ) Vaccines. 2017;2:24. https://​doi.​org/​10.​1038/​s41541-017-0024-6. eCollection 2017. Self assembling nanoparticle vaccine created using immunosense priciples creates a powerful vaccine tailored to protect humans but the principles can also incorporated full length proteins effective for immunizing other species.
104.
••Zhou Y., Melo M, Weiss R, ElBissati K, Irvine D, McLeod R. RNA replicon vaccines protect against toxoplasmosis. Immunosense and SAG1 in a noel SAPN vaccine with a new Toxoplasma CD4 eliciting peptide. In preparation. 2022. RNA replicons created using immunosense principles effetively immunize against T.gondii but SAG1 is most critical when combined with RNA encoding the peptides, emphasizing importance of SAG1 as an immunogen in future vaccines.
105.
••Zhou Y, El Bissati K, Reed S, Fox C, Alexander J, Sidney J, Sette A, Burkhard P, McLeod R. Adjuvanting designer SAPN vaccines with conventional adjvuants demonstrates superiority of GLA-SE and inability to combine the adjuvant CPG and GLA-SE. In preparation, 2022. Designer vaccines to protect humans against toxoplasmosis cannot be adjuvanted with cpg and gla-se togegether but are effective with one or the other adjuvants.
106.
••Waldman, B.S., Schwarz, D., Wadsworth, M.H., Saeij, J.P.,Shalek, A.K., Lourido, S., 2019. Identification of a master regulator of differentiation in Toxoplasma. BioRxiv660753. Available from: https://​doi.​org/​10.​1101/​660753. Regulator of bradyzoite stage switch discovered.
107.
••Elbissati K, Raczy M, ZhouY, Weber C, Solaki A, Reed S, Fox C, Alexander J, Sidney J, Sette A, Burkhard P, Hubbel J, McLeod R. In preparation 2022. Creation of a “plug ad play” strategy to create designer vaccines to protect humans and other species. GLA-se and immunosense SAPN create a potent vaccine against toxoplasmosis in HLA transgenic mice.
108.
••Chalal JS, et al Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondiichallenges with a single dose. 2016. https://​doi.​org/​10.​1073/​pnas.​1600299113. Venezuelan Equine Virus (VEEV)- based modified dendrimer nanoparticle RNA (MDNP RNA) vaccine protects against death due to Pru with HGXPRT strain Toxoplasma gondii. RNA replicons encoding full length SAG1, SAG2A, AMA1, GRA6, ROP2A, and ROP18, protect C57Bl6 mice for 175 days post challenge against this strain when replicon is incorporated in polyethylene glycol lipid nanoparticle.
109.
••Lai, B.-S., Witola, W.H., Bissati, K., El Zhou, Y., Mui, E. et al., 2012. Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc Natl Acad Sci USA. 109;(35):1418214187. Peptide or vivo morpholinos targeting essential parasite molecules such as DHFR, ENR, and Apetela 2 transcription factors can treat Toxoplasma infection.
110.
Tipparaju SK, Muench SP, Mui EJ, Ruzheinikov SN, Lu JZ, Hutson SL, Kirisits MJ, Prigge ST, Roberts CW, Henriquez FL, Kozikowski AP, Rice DW, Mcleod RL. Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J Med Chem. 2010;53:6287–300. Novel inhibitors of toxoplasma type ii fatty acid synthesis can treat toxoplasmosis.PubMedPubMedCentralCrossRef
111.
Mazumdar J, Wilson HE, Masek K, Hunter AC, Striepen B. Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii. Proc Natl Acad Sci USA. 2006;103:13192–7 Type 2 fatty acid synthesis (fas) is essential for parasite survival and organelle biogenesis.PubMedPubMedCentralCrossRef
112.
Welsch ME, Zhou J, Gao Y, Yan Y, Porter G, Gautam Agnihotri G, Li Y, Lu H, Chen Z, Thomas SB. Discovery of Potent and Selective Leads against Toxoplasma gondii Dihydrofolate Reductase via Structure-Based Design ACS. Med Chem Lett. 2016;7(12): 1124–1129. Published online 2016. https://​doi.​org/​10.​1021/​acsmedchemlett.​6b00328. Targeting Toxoplasma DHFR creates a potent inhibitor of T.gondii tachyzoites currently held by Vyera.
113.
••Mui EJ, Schiehser GA, Milhous WK, Hsu H, Roberts CW, Kirisits M, Muench S, Rice D, Dubey JP, Fowble JW, Rathod PK, Queener SF, Liu SR, Jacobus DP, McLeod R. Novel Triazine JPC-2067-B Inhibits Toxoplasma gondii In Vitro and In Vivo. PLoS Negl Trop Dis. 2008;2:e190 Novel triazine is a potent inhibitor nanomolar inhibitor of T.gondii tachyzoites as effective as a single anti-parasitic ompound as pyrimethamine and sulfadiazine acting synergistically together.PubMedPubMedCentralCrossRef
114.
••Samuel BU, Hearn B, Mack D, Wender P, Rothbard J, Kirisits MJ, Mui E, Wernimont S, Roberts CW, Muench SP, Rice DW, Prigge ST, Law AB, McLeod R. Delivery of antimicrobials into parasites. Proc Natl Acad Sci U S A. 2003;100:14281–6 Transductive peptides can deliver small molecules into tachyzoites and encysted bradyzoites creating potent inhibitors of T.gondii.PubMedPubMedCentralCrossRef
115.
••Zhou Y, Fomovska A, Muench S, Lai BS, Mui E, Mcleod R. Spiroindolone that inhibits PfATPase4 is a Potent, Cidal Inhibitor of Toxoplasma gondii tachyzoites in vitro and in vivo. Antimicrob Agents Chemother. 2014;58(3):1789–92. Sproindolone that inhibits ATPase 4 is a cidal inhibitor of T.gondii tavhyzoites. VivoPMO also is effective.PubMedPubMedCentralCrossRef
116.
••Fomovska A, Huang Q, El Bissati K, Mui EJ, Witola WH, Cheng G, Zhou Y, Sommerville C, Roberts CW, Bettis S, Prigge ST, Afanador GA, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Pieroni M, Stec J, Muench SP, et al. Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway. Antimicrob Agents Chemother. 2012;56:2666–82. https://​doi.​org/​10.​1128/​AAC.​06450-11Small molecule srreen identifies a hydroxybenzamide that disrupts the T.gondii secretory pathway creating a potent inhibitor.PubMedPubMedCentralCrossRef
117.
••Smith D et al. Toxoplasma TgATG9 is critical for autophagy and long-term persistence in tissue cysts. eLife. 2021. Autophagy protein TgATG9 is critical for long term persistence of T.gondii cysts.
118.
••Huang KI, et al. CD8 T cells cry for help. Front Cell Infect Microbiol. 9:136. https://​doi.​org/​10.​3389/​fcimb.​2019.​00136. BLIMP regulates 41BB mediated exhaustion of T cells that can be corrected by agonist antibody to 41BB. This eliminates encysted organisms. This then could make it possible to eliminate remaining tahyzoites by waking up protective immunologic mechanisms and targeting tachyzoites.
119.
••Souza SP, Splitt SD, Alvarez JA, Wizzard S, Wilson JN, Luo Z, Baumgarth N, Jensen. KDC NFkBid is required 1 for immunity and antibody responses to Toxoplasma gondii bioRxiv preprint. https://​doi.​org/​10.​1101/​2020.​06.​26.​174151. A “collaborative cross” of mice demonstrates that hypervirulent South American parasite escapes protective immunological mechanisms effective against Type I,II,III parasites. Bumble mice with a difference in NFkBid also are not protected. These studies demonstrate the importance of NKcells and specific isotypes of antibody in protection against toxoplasmosis.
120.
Borrmann S, et al. Fosmidomycin plus Clindamycin for Treatment of Pediatric Patients Aged 1 to 14 Years with Plasmodium falciparum Malaria. Antimicrob Agents Chemother. 2006;50(8):2713–8. https://​doi.​org/​10.​1128/​AAC.​00392-06Inhibitor of mevalonate pathway discovered by Jomaa and Soldati inhibits Toxoplasma and Plasmodia. When administered with clindamycin -a delayed acting inhibitor is effective but has hematologic toxicity in humans.
121.
Dimier-Poisson I et al. Mic1-3 Knockout of Toxoplasma gondii Is a Successful Vaccine against Chronic and Congenital Toxoplasmosis in Mice. Mic1-3 Knockout of Toxoplasma gondii Is a Successful Vaccine against Chronic and Congenital Toxoplasmosis in Mic October 2006. J Infect Dis. 194(8):1176-83. https://​doi.​org/​10.​1086/​507706. Knockout of microneme proteins creates lie attenuate organism that functions well to protect mice against toxoplasmosis including congenital infection.
122.
••Dimier-Poisson I, Carpentier R, Nguyen T, Dahmani F, Ducournau C, Betbeder D. Prtous nanoparticle as delivery system of complex antigens for an effective vaccine against acute and chroni Toxoplasma gondii infection. Biomaterials. Remarkable formulation of RH parasite lysate in a nanoparticle administered intranasally protects sheep and primates in a zoo ending an epidemi of deaths due to toxoplasmosis in susceptible new world primate colonies in zoos across France creates a vaccine capable of protecting multiple species of mammals. Remarkable protection with practical proof in French zoos for primates.
123.
••El Bissati K, et al. Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii. JCI Insight. 2016;1(15):e85955. https://​doi.​org/​10.​1172/​jci.​insight.​85955Combining T.gondi peptides mapped as important in immunosense system studies against toxoplasmosis in HLA Class I transgenic mice are potent as a polypeptide vaccine when admistered to these mice combined with a universal peptide eliciting CD4+T cells and GLA-SE a nanoemulsion adjuvant now in clinical use that stimulates TLR4.PubMedPubMedCentralCrossRef
124.
Lourido S, Jeschke GR, Turk BE, Sibley LD. Exploiting the unique ATP-binding pocket of toxoplasmacalcium-dependent protein kinase 1 to identifyits substrates. ACS Chem Biol. 2013;8(6):1155–62. https://​doi.​org/​10.​1021/​cb400115yCalcium dependent protein kinases are molecular targets in tachyzoite and encysted bradyzoites leading to development of small molecule inhibitor “lead compound” currently held by Vyera.PubMedPubMedCentralCrossRef
125.
••Karanovic D, Michelow IC, Hayward AR, DeRavin SS, Delmonte OM, Grigg ME, Dobbs AK, Niemela JE, Stoddard J, Alhinai Z, Rybak N, Hernandez N, Pittaluga S, Rosenzweig SD, Uzel G, Notarangelo LD. Disseminated and Congenital Toxoplasmosis in a Mother and Child with Toxoplasma Infections in Primary Immunodeficiencies. Front Immunol. 2019;10:77. https://​doi.​org/​10.​3389/​fimmu.​2019.​0007Summarizes and identifies genes and pathways in which which they function where mutations confer susceptibility to human toxoplasmosis.PubMedPubMedCentralCrossRef
126.
••Naranjo-Galvis CA, de-la-Torre A, Mantilla-Muriel LE, Beltrán-Angarita L, Elcoroaristizabal-Martín X, McLeod R, Alliey-Rodriguez N, Begeman IJ, López de Mesa C, Gómez-Marín JE, Sepúlveda-Arias JC. Genetic Polymorphisms in Cytokine Genes in Colombian Patients with Ocular Toxoplasmosis. Infect Immun. 2018;86(4):e00597-17. https://​doi.​org/​10.​1128/​IAI.​00597-17. Print 2018 Apr. PMID: Identifies importance of cytokine genes in protection against toxoplasmosis in Colombia.
127.
••Perce-da-Silva DdeS, Thays EJ, Aleixo QdoC, Motta J, Ribeiro-Alves M, Oliveira Ferreira Jde, Porto CdeMSL, Banic DM, Reis AMR. Influence of Activating and Inhibitory Killer Immunoglobulin-Like Receptors (KIR) genes on the recurrence rate of ocular toxoplasmosis in Brazil. BioRx. 10.1101/2020.09.16.299446. Identifies natural killer cell receptors in protection against recurrence of ocular toxoplasmosis in humans in Brazil.
128.
••Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, Coggins JR, Coombs GH, Milhous WK, Tzipori S, Ferguson DJ, Chakrabarti D, McLeod R. Evidence for the shikimate pathway in apicomplexan parasites. Nature. 1998:393–801-5 Plant-like metabolic pathways in apicomplexan parasites can be targeted. Apicomplexan parasites are mosaics of metabolic pathways identifying unique ways to target organellar and cytoplasmic pathways.
129.
••Zuther E, Johnson JJ, Haselkorn R, McLeod R, Gornicki P. Growth of Toxoplasma gondii is inhibited by aryloxyphenoxypropionate herbicides targeting acetyl-CoA carboxylase. Proc NatL Acad Sci U S A. 1999;96:13387-92. Targetting the plant -like acetyl-CoA carboxylase with herbicides known to inhibit this enzyme in weeds identifies two classes of small molecules capable of inhibiting apicomplexan parasites through targeting enzymes stored in the chloroplast like organelle inherited from an ancient progenitor Copydelia demonstrating this plant-like endosymbiotic organelle can be targeted. This suggests the possibility of targeting other unique organellar constituents and phylogenetically genetically distinct molecules including plant-like transcription factors as in McPhillie reference above as “Achilles heels” where these parasites are susceptible to unique methods of inhibiting these parasites.
130.
••Doggett JS, Nilsen A, Forquer I, Wegmann KW, Jones-Brando L, Yolken RH, Bordón C, Charman SA, Katneni K, Schultz T, Burrows JN, Hinrichs DJ, Meunier B, Carruthers VB, Riscoe MK. Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Natl Acad Sci U S A. 2012;109:15936–41. https://​doi.​org/​10.​1073/​pnas.​1208069109Effect of endochin-like quinolomes against cytochrome bc in Toxoplasma inhibits encysted bradyzoites in mouse models although inhibition is not 100 percent.PubMedPubMedCentralCrossRef
131.
••Kortagere S, Mui E, McLeod R, Welsh WJ. Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach. J Comput Aided Mol Des. 2011; 25:403–411. https://​doi.​org/​10.​1007/​s10822-011-9420-6. Targeting Myosin in Toxoplasma and using a computational approach with medicinal chemistry creates an inhibitor of Toxoplasma tachyzoites.
132.
133.
••Dando C, Schroeder ER, Hunsaker LA, Deck LM, Royer RE, Zhou X, Parmley SF, Vander Jagt DL. The kinetic properties and sensitivities to inhibitors of lactate dehydrogenases (LDH1 and LDH2) from Toxoplasma gondii: comparisons with pLDH from Plasmodium falciparum. Mol Biochem Parasitol. 2001;118:23–32. https://​doi.​org/​10.​1016/​S0166-6851(01)00360-7Targeting Lactate dehydrogenases of apicomplexan parasites.PubMedCrossRef
134.
••El Bissati K, Zhou Y, Paulillo SM, Raman SK, Karch CP, Reed S, Estes A, Estes A, Lykins J, Burkhard P, McLeod R. Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice. Scientific Reports (Nature) September 2020. 10:16984. Online 2020 Oct 12. https://​doi.​org/​10.​1038/​s41598-020-73210-0. Potent imunosense protein self-assembling nanoaccine adjuvanted with GLA-SE protects HLA transgenic mice demonstrating effect of peptides where genetic restriction demonstrates protection is operative for three HLA Class I supermotifs.
135.
Del Valle Mojica C, Montoya JG, McGuire J, Palma KL, Shekdar KV, McLeod R … et al. Late diagnosis of congenital toxoplasmosis with macrocephaly in two dizygotic twins after incidental detection of leukocoria: a case report. J Peds Infect Dis. 2021. Late symptomatic infection is treated medically in dizygotic twins.
136.
137.
••Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, El Bissati K, Zhou Y, Suzuki Y, Lee D, Woods S, Sommerville C, Henriquez FL, Roberts CW, McLeod R. Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice. Hum Immunol. 2012;73:1–10. Self assembling nanoparticle containing GRA7(peptide 20-29) elicits a protective immune response when administered with GLA-SE to HLA B0702 transgenic mice.
138.
••Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 2010;6:12. Self assembling nanoparticle-peptides elicit protective immunity in HLA-A*1101  transgenic mice.
139.
••Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R. Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLAA*0201. Vaccine. 2011;29:754–62. GLA-SE and HLA02 binding-peptides elicit protective immunity in HLA-A*0201 transgenic mice.
Metadata
Title
Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances “Take a Village”
Authors
Mariangela Soberón Felín
Kanix Wang
Aliya Moreira
Andrew Grose
Karen Leahy
Ying Zhou
Fatima Alibana Clouser
Maryam Siddiqui
Nicole Leong
Perpetua Goodall
Morgan Michalowski
Mahmoud Ismail
Monica Christmas
Stephen Schrantz
Zuleima Caballero
Ximena Norero
Dora Estripeaut
David Ellis
Catalina Raggi
Catherine Castro
Davina Moossazadeh
Margarita Ramirez
Abhinav Pandey
Kevin Ashi
Samantha Dovgin
Ashtyn Dixon
Xuan Li
Ian Begeman
Sharon Heichman
Joseph Lykins
Delba Villalobos-Cerrud
Lorena Fabrega
José Luis Sanchez Montalvo
Connie Mendivil
Mario R. Quijada
Silvia Fernández-Pirla
Valli de La Guardia
Digna Wong
Mayrene Ladrón de Guevara
Carlos Flores
Jovanna Borace
Anabel García
Natividad Caballero
Claudia Rengifo-Herrera
Maria Theresa Moreno de Saez
Michael Politis
Stephanie Ross
Mimansa Dogra
Vishan Dhamsania
Nicholas Graves
Marci Kirchberg
Kopal Mathur
Ashley Aue
Carlos M. Restrepo
Alejandro Llanes
German Guzman
Arturo Rebellon
Kenneth Boyer
Peter Heydemann
A. Gwendolyn Noble
Charles Swisher
Peter Rabiah
Shawn Withers
Teri Hull
David Frim
David McLone
Chunlei Su
Michael Blair
Paul Latkany
Ernest Mui
Daniel Vitor Vasconcelos-Santos
Alcibiades Villareal
Ambar Perez
Carlos Andrés Naranjo Galvis
Mónica Vargas Montes
Nestor Ivan Cardona Perez
Morgan Ramirez
Cy Chittenden
Edward Wang
Laura Lorena Garcia-López
Guillermo Padrieu
Juliana Muñoz-Ortiz
Nicolás Rivera-Valdivia
María Cristina Bohorquez-Granados
Gabriela Castaño de-la-Torre
Juan David Valencia Hernandez
Daniel Celis-Giraldo
Juan Alejandro Acosta Dávila
Elizabeth Torres
Manuela Mejia Oquendo
José Y. Arteaga-Rivera
Dan L Nicolae
Andrey Rzhetsky
Nancy Roizen
Eileen Stillwaggon
Larry Sawers
Francois Peyron
Martine Wallon
Emanuelle Chapey
Pauline Levigne
Carmen Charter
Migdalia De Frias
Jose Montoya
Cindy Press
Raymund Ramirez
Despina Contopoulos-Ioannidis
Yvonne Maldonado
Oliver Liesenfeld
Carlos Gomez
Kelsey Wheeler
Samantha Zehar
James McAuley
Denis Limonne
Sandrine Houze
Sylvie Abraham
Raphael Piarroux
Vera Tesic
Kathleen Beavis
Ana Abeleda
Mari Sautter
Bouchra El Mansouri
Adlaoui El Bachir
Fatima Amarir
Kamal El Bissati
Ellen Holfels
David Frim
David McLone
Richard Penn
William Cohen
Alejandra de-la-Torre
Gabrielle Britton
Jorge Motta
Eduardo Ortega-Barria
Isabel Luz Romero
Paul Meier
Michael Grigg
Jorge Gómez-Marín
Jagannatha Rao Kosagisharaf
Xavier Sáez Llorens
Osvaldo Reyes
Rima McLeod
Publication date
01-09-2022
Publisher
Springer US
Published in
Current Pediatrics Reports / Issue 3/2022
Electronic ISSN: 2167-4841
DOI
https://doi.org/10.1007/s40124-022-00268-x

Other articles of this Issue 3/2022

Current Pediatrics Reports 3/2022 Go to the issue

Adolescent Medicine (MA Goldstein, Section Editor)

Pediatric to Adult Transition for Adolescents and Young Adults with Kidney Transplant

International Health (EG Lago and N Gupta, Section Editors)

Building Programs to Eradicate Toxoplasmosis Part II: Education

International Health (EG Lago and N Gupta, Section Editors)

Building Programs to Eradicate Toxoplasmosis Part III: Epidemiology and Risk Factors

International Health (EG Lago and N Gupta, Section Editors)

Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview